Thrombopoietin Receptor Agonist clinical trials
Its developmentBy Novartis and Chongqing Peg-Bio Biopharm, step by step2 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Thrombopoietin Receptor Agonist is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Thrombopoietin Receptor Agonist studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Chongqing Peg-Bio Biopharm Co., Ltd. (1) · Peking Union Medical College Hospital (1) · Novartis Pharmaceuticals (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · The First Affiliated Hospital of Zhengzhou University (1)
Often tested with
Tested in the same studies.
Cyclosporine (1) · Romiplostim (1) · Ianalumab (1) · Recombinant human thrombopoietin (1)
Studies
Open first, then newest update. How each study uses Thrombopoietin Receptor Agonist is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)RecruitingPhase 2Novartis PharmaceuticalsNCT07421167Written as thrombopoietin receptor agonist (TPO-RA)
- CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAANot yet recruitingPhase 2Peking Union Medical College HospitalNCT07558434Written as thrombopoietin receptor agonist (TPO-RA)
- TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 YearsRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT04890041Written as TPO-RA
- Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)CompletedPhase 1Chongqing Peg-Bio Biopharm Co., Ltd.NCT06880081Written as PN20 treatment
- A Clinical Study of Herombopag in Tumors-associated ThrombocytopeniaStatus unknownPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT05350956Written as TPO-RA (Herombopag)
Given beside what is tested · 5 — Thrombopoietin Receptor Agonist is usual care or a partner of the new treatment
- Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune ThrombocytopeniaRecruitingPhase 4Institute of Hematology & Blood Diseases Hospital, ChinaNCT07788456Written as thrombopoietin receptor agonist(TPO-RA), including but not limited to hetrombopag or eltrombopag.
- TPO-RA Plus Baricitinib vs. TPO-RA for ITPNot yet recruitingPhase 2Peking University People's HospitalNCT07669675Written as TPO-RA
- Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCTNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT05669079Written as Recombinant human thrombopoietin / thrombopoietin receptor agonist
- Decitabine for Poor Graft Function Post Allo-HSCTCompletedPhase 3The First Affiliated Hospital of Soochow UniversityNCT05907499Written as Thrombopoietin Receptor Agonist
- CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAAWithdrawnPhase 2Peking Union Medical College HospitalNCT07523009Written as Thrombopoietin Receptor Agonist